Enterolactone

Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity[1]. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis[2].

Product Specifications

CAS Number

[78473-71-9]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Apoptosis; Endogenous Metabolite

Type

Natural Products

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/enterolactone.html

Purity

99.0

Solubility

DMSO : 30 mg/mL (ultrasonic; warming)

Smiles

O=C1OC[C@H](CC2=CC=CC(O)=C2)[C@H]1CC3=CC=CC(O)=C3

Molecular Formula

C18H18O4

Molecular Weight

298.33

Precautions

H315, H319, H335

References & Citations

[1]Bigdeli B, et al. Enterolactone: A novel radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis. Toxicol Appl Pharmacol. 2016;313:180-194.|[2]Mali AV, et al. Enterolactone modulates the ERK/NF-κB/Snail signaling pathway in triple-negative breast cancer cell line MDA-MB-231 to revert the TGF-β-induced epithelial-mesenchymal transition. Cancer Biol Med. 2018;15 (2) :137-156.